Boehringer Ingelheim GmbH
Member: Silver
Since: 06.12.2013
Since: 06.12.2013
Leoforos Andrea Syngrou 340, 176 73 Kallithea, Greece
-
08.03.2019Boehringer Ingelheim: Novel antibody shows potential to transform treatment of rare form of psoriasis
Published in The New England Journal of Medicine -
17.12.2018Boehringer Ingelheim announces the first interim results of VARGADO
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer -
14.11.2018Boehringer Ingelheim: Initial results from EMPRISE real-world evidence study
Empagliflozin was associated with a 44 percent relative risk reduction in hospitalisation for heart failure -
04.10.2018Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Trajenta® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes -
17.09.2018Boehringer Ingelheim: New study results provide evidence that Ofev® slows progression of IPF beyond four years with consistent safety
Results from INPULSIS®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet Respiratory Medicine - MORE